• 제목/요약/키워드: breast carcinoma

검색결과 588건 처리시간 0.032초

Prognostic Role of PTEN Gene Expression in Breast Cancer Patients from North-East Iran

  • Golmohammadi, Rahim;Rakhshani, Mohammad Hassan;Moslem, Ali Reza;Pejhan, Akbar
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제17권9호
    • /
    • pp.4527-4531
    • /
    • 2016
  • Background: PTEN protein is one of the most important tumour suppressor factors which is detectable by immunohistochemistry. The goal of the present study was to investigate the prognostic role of PTEN gene expression in breast cancer patients. Materials and Methods: This descriptive-analytical study was conducted on 100 breast cancer patients referred to Sabzevar hospitals in the north-east of Iran between 2010 and 2011, who were followed up to 2015. PTEN gene expression in tissue samples was determined using specific monoclonal antibodies and data were analyzed using Chi-square test and Fisher's exact test. Patient survival was analyzed after 4 years of follow-up using the Cox regression model. Results: PTEN gene expression was evident in 70 of 100 cnacer samples but was found at high levels in all non-cancer samples. There was an inverse significant relationship between PTEN gene expression and tumour stage or tumour grade (p<0.001). The expression of PTEN in invasive ductal tumours was lower than in non-invasive tumours. There was also an inverse significant relationship between the hazard of death and PTEN gene expression (p<0.001). In addition, there was an inverse significant relationship between tumour stage and hazard of death (p<0.001). Conclusion: These findings indicate that lack of PTEN gene expression can be a sign of a worse prognosis and poor survival in breast cancer cases.

40대 유방암 생존자의 우울·불안 위험요인 (Risk Factors for Depression and Anxiety among Breast Cancer Survivors in Their 40s)

  • 황숙연
    • 한국콘텐츠학회논문지
    • /
    • 제15권2호
    • /
    • pp.313-323
    • /
    • 2015
  • 본 연구는 우리나라에서 가장 유방암 발생률이 높은 40대 유방암 생존자들의 우울과 불안의 정도를 파악하고 그 위험요인들을 검토하기 위해 수행되었다. 자료 수집은 유방암으로 진단 받은 40-49세 유방암 생존자 중 연구에 동의하고 설문지를 완성한 609명을 대상으로 이루어졌다. CES-D와 GAD-7을 사용하여 측정된 우울과 불안의 평균점수는 각각 16.35(SD=9.24), 4.25(SD=4.17)였으며, 절단점을 기준으로 우울군은 전체의 47.7%, 불안군은 10.3%로 나타났다. BPI-K로 측정된 통증강도 평균은 1.91(SD=1.60)이었으며, 전체의 82.8%가 통증을 호소하였고 10.9%가 중증도 이상의 통증을 보고하였다. 위계적 회귀분석결과 최종모델에서 통증 일상생활방해정도, 직업 없음, 동거가족유형과 과거 정신과 질환이 우울의 유의미한 위험요인으로 나타났고, 불안의 위험요인은 통증 일상생활방해정도, 직업 없음 및 과거 정신과질환으로 나타났다. 이러한 결과는 우리나라 40대 유방암 생존자의 우울과 불안 유병률이 높으며, 우울과 불안의 위험요인에 초점을 두어 위험군에 대한 적절한 심리사회적 개입이 제공되어야 함을 지적해주고 있다.

비침습 유방암의 양·한방 협진 표준임상경로 모형 개발 (Development of Clinical Pathway Model in Integrative Korean Medicine: Treatment of Non-invasive Breast Cancer)

  • 조수연;고성규;박선주
    • 대한예방한의학회지
    • /
    • 제26권1호
    • /
    • pp.11-23
    • /
    • 2022
  • Objectives : The aim of this study was to develop a clinical pathway (CP) model for the integrative treatment of non-invasive breast cancer, with western medicine and Korean traditional medicine. Methods : The checklist model was composed in four types according to the target patients: DCIS inpatients, DCIS outpatients, LCIS inpatients, LCIS outpatients. The vertical axis of the pathway consists of 11 categories of actions applied to the patient. The horizontal axis was in accordance with the flow of time, comprising three periods during inpatient care and seven periods during outpatient care. In addition, CP was also composed in flow chart form. The pathway model was developed through a literature review of clinical practice guidelines, conference publications, papers, books, and websites. Results : The integrative CP model for non-invasive breast cancer was developed. Conclusions : The goal of the CP suggested in this study was to improve non-invasive breast cancer patients' quality of life and to supplement conventional treatment, by alleviating the side effects. The model developed through this study could serve as the basis when developing CPs in a real-world integrative medical environment. This could lead to a reduction in cost and time for CP development, thus bringing about efficiency in the clinical setting.

The genomic landscape associated with resistance to aromatase inhibitors in breast cancer

  • Kirithika Sadasivam;Jeevitha Priya Manoharan;Hema Palanisamy;Subramanian Vidyalakshmi
    • Genomics & Informatics
    • /
    • 제21권2호
    • /
    • pp.20.1-20.10
    • /
    • 2023
  • Aromatase inhibitors (AI) are drugs that are widely used in treating estrogen receptor (ER)-positive breast cancer patients. Drug resistance is a major obstacle to aromatase inhibition therapy. There are diverse reasons behind acquired AI resistance. This study aims at identifying the plausible cause of acquired AI resistance in patients administered with non-steroidal AIs (anastrozole and letrozole). We used genomic, transcriptomic, epigenetic, and mutation data of breast invasive carcinoma from The Cancer Genomic Atlas database. The data was then separated into sensitive and resistant sets based on patients' responsiveness to the non-steroidal AIs. A sensitive set of 150 patients and a resistant set of 172 patients were included for the study. These data were collectively analyzed to probe into the factors that might be responsible for AI resistance. We identified 17 differentially regulated genes (DEGs) among the two groups. Then, methylation, mutation, miRNA, copy number variation, and pathway analyses were performed for these DEGs. The top mutated genes (FGFR3, CDKN2A, RNF208, MAPK4, MAPK15, HSD3B1, CRYBB2, CDC20B, TP53TG5, and MAPK8IP3) were predicted. We also identified a key miRNA - hsa-mir-1264 regulating the expression of CDC20B. Pathway analysis revealed HSD3B1 to be involved in estrogen biosynthesis. This study reveals the involvement of key genes that might be associated with the development of AI resistance in ER-positive breast cancers and hence may act as a potential prognostic and diagnostic biomarker for these patients.

Peanut sprout tea extract inhibits lung metastasis of 4T1 murine mammary carcinoma cells by suppressing the crosstalk between cancer cells and macrophages in BALB/c mice

  • Jae In Jung;Hyun Sook Lee;Jaehak Lee;Eun Ji Kim
    • Nutrition Research and Practice
    • /
    • 제17권5호
    • /
    • pp.917-933
    • /
    • 2023
  • BACKGROUND/OBJECTIVES: As peanuts germinate, the content of the components beneficial to health, such as resveratrol, increases within the peanut sprout. This study examined whether the ethanol extract of peanut sprout tea (PSTE) inhibits breast cancer growth and metastasis. MATERIALS/METHODS: After orthotopically injecting 4T1 cells into BALB/c mice to induce breast cancer, 0, 30, or 60 mg/kg body weight/day of PSTE was administered orally. Angiogenesis-related protein expression in the tumors and the degree of metastasis were analyzed. 4T1 and RAW 264.7 cells were co-cultured, and reverse transcription polymerase chain reaction was performed to measure the crosstalk between breast cancer cells and macrophages. RESULTS: PSTE reduced tumor growth and lung metastasis. In particular, PSTE decreased matrix metalloproteinase-9, platelet endothelial cell adhesion molecule-1, vascular endothelial growth factor-A, F4/80, CD11c, macrophage mannose receptor, macrophage colony-stimulating factor, and monocyte chemoattractant protein 1 expression in the tumors. Moreover, PSTE prevented 4T1 cell migration, invasion, and macrophage activity in RAW 264.7 cells. PSTE inhibited the crosstalk between 4T1 cells and RAW 264.7 cells and promoted the macrophage M1 subtype while inhibiting the M2 subtype. CONCLUSIONS: These results suggest that PSTE blocks breast cancer growth and metastasis to the lungs. This may be because the PSTE treatment inhibits the crosstalk between mammary cancer cells and macrophages and inhibits the differentiation of macrophages into the M2 subtype.

Genetic Suppressor Elements that Halt the Proliferation of Breast Carcinoma Cells

  • Primiano, Thomas
    • 대한약학회:학술대회논문집
    • /
    • 대한약학회 2002년도 Proceedings of the Convention of the Pharmaceutical Society of Korea Vol.2
    • /
    • pp.98-114
    • /
    • 2002
  • The completion of the draft sequence of the human genome has provided us with a partial list of known and putative human genes, the total number of which is estimated between 30, 000 and 45, 000 (1, 2). These genes provide many potential targets for drugs, some of which may be useful in stopping the growth of cancers. The development of gene-targeting anticancer drugs could be greatly facilitated by the ability to narrow down the list of human genes to those that are necessary for the growth of tumor cells. (omitted)

  • PDF